WuXi unveils new production capabilities at Changzhou campus amid expansion push

WuXi STA, a part of WuXi AppTec, unveiled new large-scale oligonucleotide and peptide manufacturing capabilities at its Changzhou production campus.

The 30,570-square-foot oligonucleotide facility features four large-scale oligonucleotide production lines and more than 20 small- to midscale production lines. The 22,260-square-foot peptide plant has three new production lines with reactors that can accommodate up to 1,000 liters.

WuXi STA, like many in the CDMO space, has been on a production expansion tear in recent years, spurred on by advances in cell and gene therapies as well as other novel treatments.

The latest expansion comes a week after WuXi STA opened the doors of its high-potency active pharmaceutical ingredient production facility at the Changzhou site located in Jiangsu, China. That facility boasts reactors ranging from 250 liters to 3,000 liters and also has flow chemistry and milling technology. 

Earlier this year, the company said its Waigaoqiao facility near Shanghai passed its first FDA drug product preapproval inspection and two additional preapproval inspections by China’s regulatory agency, the NMPA.

Looking forward, WuXi STA said it expects to open a new pharmaceutical manufacturing campus in Middletown, Delaware, in 2024.